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Strengths and limitations of this study
 ► Validated measures will be used for evaluating the 
outcomes and the independent variables.
 ► The overall quality of the study will be maintained 
through random spot-checks.
 ► The study results can be generalised to all cancer 
patients presenting at private tertiary care hospitals 
in Pakistan.
 ► To compare the quality of life and resilience within 
the two groups of patients, subgroup analysis will be 
performed by stratification.
AbStrACt
background Cancer is a devastating disease and has 
detrimental effects on the quality of life (QoL) of cancer 
survivors and interferes with their treatment compliance. 
The aim of the study is to assess resilience and QoL 
among cancer survivors and to evaluate the important 
factors affecting their resilience and QoL, with respect to 
the Pakistani cultural context.
Method and analysis A cross-sectional study will be 
conducted at a tertiary care hospital in Karachi, Pakistan. 
A minimum sample size of 250 head and neck cancers 
and 250 brain tumour survivors with 10% inflation for 
non-response rate will be required. The SD of QoL and 
resilience will range from 16.5 to 40.8 for head and neck 
cancer, and 12.7 to 34.1 for brain tumour, at 5% level of 
significance, with 2.5 precision. QoL will be assessed by 
European Organization for Research and Treatment of 
Cancer (EORTC) QLQ-C30, EORTC QLQ-H&N35 and EORTC 
QLQ-BN20 and resilience will be evaluated by Wagnild 
and Young’s 14-item scale. Mean±SD will be reported 
for resilience and QoL scores. Unadjusted and adjusted 
β-coefficients, with 95% CI, will be reported by using 
multiple linear regression analysis. Correlation analysis 
will also be performed using Pearson or Spearman 
rank correlation coefficients. A p value of <0.05 will be 
considered significant.
Ethics and dissemination Ethical approval has been 
obtained from the Aga Khan University Pakistan’s Ethical 
Review Committee. Written informed consent will be taken 
from the participants by trained research assistants. A 
trained psychologist will provide on-spot counselling to the 
participants and those identified with severe depression 
will be referred to a psychiatrist. The study materials will 
be kept under lock and key and the electronic data base 
will be password protected and will only be accessed by 
the research team. The study findings will be disseminated 
through publications conferences and workshops and 
research briefs.
trial registration number  Clinicaltrials. gov registry 
(NCT03466762).
bACkground
Globally, cancer is the second leading cause 
of death.1 Approximately 70% of the deaths 
from cancer occur in the lower middle 
income countries. Head and neck cancers 
are the sixth most common cancers world-
wide, with ~630 000 new cases diagnosed 
annually, causing 350 000 deaths.2 3 Globally, 
brain tumours are also a significant source of 
cancer-related morbidity and mortality, with 
an overall incidence of 4–5/100 000 cases 
annually, contributing to 2% of all cancer 
deaths.4 And in Pakistan ~150 000 new cases 
of cancer are diagnosed annually, causing 
60%–80% deaths.5
Conventionally, the endpoints of medical 
care for cancer patients are focused on 
survival rate, local control rate or complica-
tion rate.6 These assessments do not capture 
the patients’ mental and emotional well-
being,6 although the diagnosis of cancer 
considerably affects a patient’s emotional and 
psychological status7
Cancer patients suffer clinically important 
symptoms of emotional distress such as 
depression and anxiety8 that reduces their 
quality of life (QoL) and resilience and inter-
feres with their treatment compliance.9 10 
Studies have found that cancer patients with 
similar diseases and treatment status have 
significantly different QoLs.11 12 It is believed 
that resilience is the main factor that causes 
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Figure 1 Conceptual framework of resilience and quality 
of life for cancer survivors adapted from ‘the adolescent 
resilience model’.47
patients with similar situations to have different percep-
tions about their QoL.13 14
Resilience is an important trait that contributes to 
a person’s mental and physical well-being. Evidence 
suggests that resilience is related to motivation. This 
motivation to recover from physical or psychological 
traumatic events15 16 minimises the impact of risk factors, 
thus increasing a person’s ability to deal with challenges 
of life.17 Resilience, thus protects against psychosocial 
health-related issues, such as depression, anxiety, fear and 
helplessness, and helps to reduce their associated nega-
tive effects.18
Resilience has an important impact on the QoL of a 
cancer patient. Hence, over the last few years, QoL has 
become an important health-related outcome measure 
with regard to communities and healthcare systems. This 
outcome measure is based on multidimensional concept 
that incorporates: the subjective perceptions of posi-
tive and negative aspects of cancer symptoms, physical, 
emotional, social,cognitive functions, the disease symp-
toms and the side effects of treatment.7 19
There are several positive and negative factors that can 
influence a cancer patient’s resilience and QoL. These 
are: illness-related risk, which include perceived illness, 
ambiguity and complexity, stress of symptoms, severity of 
illness; family protective factors, which include perceived 
social support from family and socioeconomic variables; 
social protective factors, which include perceived social 
support from friends, influence of others with similar 
conditions and perceived support from providers; indi-
vidual risk factors including evasive, emotive and fatalistic 
coping measures/strategies; individual protective factors, 
which include confrontive, optimistic and supportant 
coping, along with hope and spiritual factors (figure 1).
Studies have examined the influence of psycholog-
ical resilience among cancer patients.20 21 These studies 
from different parts of the world suggest that resilience 
is a protective factor against distress among cancer survi-
vors22–26 which indicates that cancer patients with high 
resilience require less psychosocial support to manage 
their stressful conditions, as compared with those with low 
resilience.20 One study reports that resilience mediates 
between cancer symptoms and distress and QoL among 
cancer survivors. Hence, resilience plays an important 
role in protecting them against the adverse effects of 
cancer symptoms.22 A systematic review of 24 studies on 
head and neck cancer patients reports that distress-re-
lated variables (depression, anxiety and distress) have a 
negative association with QoL outcomes.27
Moreover, resilience is a critical component for QoL 
at all stages; during diagnosis, treatment, survivorship 
and palliative care. It is an important trait for promoting 
positive psychosocial well-being. Early identification 
of psychological factors associated with post-treatment 
QoL is essential among those at increased risk of poorer 
outcomes, as this can aid in the development of interven-
tions to improve their QoL.27
Limited evidence is available from the Pakistani context 
regarding resilience and QoL among cancer patients. To 
the best of the researchers’ knowledge, this will be the 
first in-depth study to evaluate resilience and QoL among 
head and neck cancer and brain tumour patients in Paki-
stan. Resilience and QoL among them changes over time 
and may be modifiable towards increased well-being. This 
study will, therefore, enable designing of interventions in 
the future to improve resilience and QoL. In the light of 
literature, the objectives of this study are:
1. To determine the resilience and the QoL scores for 
head and neck cancer and brain tumour patients, at 
least 4 weeks post-treatment.
2. To evaluate important factors associated with resilience 
and QoL among head and neck cancer and brain tu-
mour patients, at least 4 weeks post-treatment.
3. To examine the relationship between resilience and 
the QoL for head and neck cancer and brain tumour 
patients, at least 4 weeks post-treatment.
MEthodS
Study design
To evaluate resilience and QoL among head and neck 
cancer and brain tumour patients and their associ-
ated factors an analytical cross-sectional study will be 
conducted. Resilience and QoL will be measured at least 
4 weeks post-treatment.
Study setting
The study will be conducted at the Aga Khan University 
Hospital (AKUH) which is a Joint Commission Inter-
national Accredition (JCIA-accredited) hospital, in 
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Figure 2 Participants recruitment plan flow diagram.
Karachi-Pakistan. Karachi is the largest metropolitan city 
of Pakistan, a home to all major ethnicities living in this 
country. Aga Khan University Hospital (AKUH) is one 
of the largest private tertiary care hospitals that cater to 
different ethnic and socioeconomic groups of popula-
tion in Karachi. The participants will be recruited from 
the surgical/oncology clinics at AKU. It has a multidisci-
plinary team that provides comprehensive care to cancer 
patients. The proposed duration of data collection will be 
4–6 months.
Study participants
Men and women aged 18 years and above, who have 
received treatment for brain tumour and head and neck 
cancer at AKUH, fulfilling the below eligibility criteria, 
will be recruited. According to recent data, the preva-
lence of head and neck cancer is escalating in Pakistan 
and limited information is available about their QoL 
brain tumour also is an understudied area in Pakistan 
and there is dearth of information regarding their QoL. 
To maintain internal validity, the participants will be 
studied based on assumptions pertaining to their respec-
tive group.
Eligibility criteria
Inclusion criteria
1. Individuals aged 18 years and above, who have received 
treatment at AKUH for head and neck cancer or brain 
tumour.
2. Cancer survivors living in Pakistan for at least 3 months.
3. Patients who will give consent to participate in the 
study.
Exclusion criteria
1. Known cases of any psychiatric illness leading to dis-
ability (eg, manic disorder, schizophrenia and so on) as 
confirmed by medical records, will be excluded from 
the study as they may be on medications that might 
distort the results.
2. Patients on antidepressants prescribed by a psychiatrist
3. Participants with physical comorbidities, stroke and 
renal failure, will be excluded because these are debili-
tating diseases that will distort the results. Patients with 
Cardiovascular Diseases (CVD)/heart disease, diabetes 
or Chronic Obstructive Pulmonary Disease (COPD) 
will not be excluded as every 4th Pakistani suffers from 
cardiovascular risk factors. If patient with these condi-
tions are excluded, the majority of the participants will 
be ineligible and the required sample size will not be 
achieved. However, these comorbid conditions will be 
adjusted during analysis.
Sampling technique
Purposive sampling technique will be used for selecting 
the participants. The target population, that is, brain 
tumour and head and neck cancer patients who have 
received cancer treatment, will be approached by 
trained research assistants. The research assistants will be 
informed about the possible study participants who will 
be coming in for their appointment, by the nurse. On the 
day of appointment, the participants will be screened for 
eligibility and if they fulfil the eligibility criteria and give 
consent to participate, they will be enrolled in the study 
(figure 2).
Sample size calculation
Head and neck cancer
The sample size has been calculated based on mean QoL 
and resilience scores for head and neck cancer patients 
from previous studies. It has been calculated using one 
population mean formula, based on a SD range of 16.5–
40.8, 5% level of significance with precision of 2.5, and 
by adjusting the sample size for 10% non-response rate. 
The minimum sample size has been estimated to be 
250.6 14 28–31
Brain tumour
The sample size has been calculated based on previ-
ously reported estimates for QoL and resilience among 
patients with brain tumours. It has been calculated using 
one population mean formula, based on a SD range of 
12.7–34.1, 5% level of significance with precision of 2.5, 
and by adjusting the sample size for 10% non-response 
rate. The minimum sample size has been estimated to be 
250.32–35
Assessment tools
Resilience (Wagnild and Young’s 14 items)
Resilience is the ability to rebound or spring back, the 
power of something to resume its original shape or posi-
tion after compression or bending.36 Resilience is also 
defined as the ‘capacity of individuals exposed to a nega-
tive event, to maintain stability and healthy physical and 
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psychological functioning. It is a defense mechanism, 
which permits people to grow in the face of adversity.’37 
The resilience tool that will be used has two versions; 
a long 25-item and short 14-item scale, using a 7-point 
rating likert scale. It comprises the five core characteristics 
of resilience, which include purposeful life, perseverance, 
equanimity, self-reliance and existential loneliness.38 A 
high score represents better resilience. The respondent’s 
choice ranges from 1 (strongly disagree) to 7 (strongly 
agree). The scale uses total scores rather than scores of 
individual items. To measure resilience, the validated 
Urdu version of the resilience scale 14 (RS-14), which 
indicates moderate negative correlation of resilience with 
depression and anxiety (r=−0.31), and moderate positive 
significant correlation of resilience with life satisfaction 
(r=0.40) will be used. The test–retest correlation coeffi-
cients and Cronbach’s alpha for RS-14 are 0.49 and 0.76, 
respectively.39
QoL (EORTC QLQ-C30, EORTC QLQ-H&N35 and EORTC QLQ-BN20)
QoL is defined by the WHO as ‘Individual’s perceptions 
of their position in life in the context of the culture and 
value systems and their goals, expectations, standards 
and concerns’.40 The QoL of the cancer survivors will 
be assessed by the European Organization for Research 
and Treatment of Cancer (EORTC) QLQ-C30 tool.41 It is 
composed of multi-item scales and single-item measures. 
These include five functional scales, three symptom 
scales, a global health status QoL scale and six single 
items. All the scales and single-item measures scores 
range from 0 to 100. A high score on the scale represents 
a higher response level. Specific questionnaires will also 
be administered to evaluate the QoL of patients with 
brain tumours and head and neck cancer via EORTC 
QLQ-BN20 and EORTC QLQ-H&N35, respectively. Since 
the tool has not been validated in Urdu, therefore, in 
this study content validation will be conducted through 
a panel of experts and the content validity index (CVI) 
will be calculated. The panel of experts will comprise 
head and neck surgeons, neurosurgeons, an oncologist, 
an epidemiologist, a biostatistician and a psychologist. 
They will be asked to provide their expert suggestions 
for improving the tool according to the Pakistani cultural 
context, in Urdu. Each and every expert will rate the tool 
regarding the relevancy and clarity of each question. The 
responses will be rated on a scale from not relevant to 
highly relevant. Based on expert scores, the CVI will be 
calculated. CVI quantifies the level of content validity by 
calculating the percentage agreement between experts.42 
CVI of >0.8 indicates high level of agreement among the 
experts.43 Permission has been granted by the QoL tool 
developers for content validation.
Sociodemography and clinical characteristics
The information on demographic variables will be 
collected on aspects like; age, gender, ethnicity, educa-
tion, family status, number of people actively working, 
monthly household income and employment status 
of the individuals. The socioeconomic determinant 
will include education, occupation and family income. 
Information on comorbid conditions such as hyperten-
sion, diabetes, cardiovascular disease, addiction history 
(including smoking and substance abuse) will also be 
evaluated. Data on important major recent life events, 
such as death of child, spouse or any other event that has 
affected their lives will also be collected. Clinical charac-
teristics and management of brain tumour and head and 
neck cancer will also be assessed by taking information 
from the patients on tumour type, site of tumour, type of 
surgery, type of chemotherapy and/or radiotherapy.
Psychosocial characteristics
The participants’ depression and anxiety will be assessed 
using the Hospital Anxiety and Depression Scale 
(HADS),44and social support will be determined via the 
Enriched Social Support Instrument (ESSI).9
hospital anxiety and depression (hAdS)
The Hospital Anxiety and Depression Scale (HADS) will 
be administered to assess depression and anxiety among 
the participants. This tool was developed to assess depres-
sion, anxiety and emotional distress among patients who 
were treated for a variety of clinical problems. HADS 
encompasses 14 items, equally subdivided into two 
scales, one measuring anxiety and the other depression. 
For instance, the item ‘Worrying thoughts go through 
my mind’ assesses anxiety, whereas the item ‘I have lost 
interest in my appearance’ evaluates depression. All the 
responses are on an ordinal four-point scale.44 To measure 
anxiety and depression, the Urdu version of HADS will be 
used.45
Social support by ESSI
Social support can ease the coping process, or help 
people overcome or adapt to a stressful event. The ESSI 
is a 7-item scale that primarily measures functional social 
support and emotional support. A total score of 18 or 
less on items 1, 2, 3, 5 and 6 is considered as low social 
support.9 To assess social support, the validated Urdu 
version of ESSI, with a CVI for relevance, and clarity of 
0.95 and 0.97, respectively, and Cronbach’s alpha 0.8246 
will be used.
Explanatory questions to evaluate culturally relevant theme
Lastly, an explanatory questionnaire will be administered 
to examine the factors that have affected the lives of the 
cancer patients and also to examine the different coping 
tactics used by the patients and their families to combat 
this disease.
Statistical analysis
Analysis will be performed using the STATA V.12. 
Descriptive statistics will be computed for categorical vari-
ables by computing their frequencies and percentages, 
and the quantitative variables will be computed by their 
mean±SD/median (IQR), as appropriate. Mean scores 
will be reported for resilience and QoL. The multiple 
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linear regression technique will be used to evaluate the 
effect of independent variables on the outcomes—re-
silience and QoL for head and neck patients and brain 
tumour patients. Adjusted β-coefficients with 95% CI will 
be reported. A p value of <0.05 will be considered statis-
tically significant. To assess the relationship between 
resilience and QoL, correlation analysis will also be 
performed, using the Pearson or Spearman rank correla-
tion coefficients as appropriate.
Ethical considerations
Participants will be recruited from the surgical/oncology 
clinics of AKUH. Written informed consent will be taken 
from the participants by trained research assistants, after 
explaining the study procedure and its potential risks and 
benefits to them.
In this particular study, the participants might feel 
anxious/uncomfortable during the interview, especially 
when their stress and depression level will be evaluated. 
To overcome this, proper training will be given to the 
research team for sensitive questions. On spot counselling 
by a trained psychologist will be provided to the partici-
pants identified as having depression. Those patients 
identified with severe depression especially with suicidal 
intentions will be referred to a psychiatrist.
Strict confidentiality and privacy rules will be main-
tained and the participants’ information will be kept 
confidential. Interviews will be conducted in a separate 
room. All study materials containing personal identifiers 
will be kept in a locked file cabinet. A unique study iden-
tification number will be assigned to each participant. 
Data will be entered in a password-protected electronic 
database that will only be accessible by the research team.
Patient and public involvement
This will be a cross-sectional study design and the partic-
ipants will be interviewed, regarding their sociodemo-
graphic factors, anxiety, depression, resilience and QoL, 
by trained research assistants.
The study findings will be disseminated to different 
stakeholders, such as healthcare professionals, rehabilita-
tion experts, psychologists and cancer patients through: 
publications at local, national and international journals, 
presentations at conferences and workshops and through 
research briefs.
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